STL Therapy: Targeted RNA Virus Therapy for Cancer Treatment

STL Therapy is an advanced cancer treatment utilizing synthetic single-stranded positivesense RNA (ssRNA+) viruses with a complementary defect mechanism to precisely target
cancer cells, particularly for lung, liver, and brain cancers. Leveraging mRNA platforms,
viral vectors, and AI, STL Therapy is designed for rapid deployment in 2025, transitioning
from laboratory to clinical trials within 1–2 years. With high specificity, absolute safety via
a kill switch, and costs below $20,000 per patient, STL Therapy offers a practical solution
to improve cancer outcomes.